Skip to main content

Apellis Pharmaceuticals Inc(APLS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low40.83
Day High40.88
Open:40.85
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

The sectors that could see better earnings from the Iran war

So far, season two of Trade Off has highlighted how volatility can skew performance in the short run
Motley Fool
Why Biogen Stock Got Mashed on Monday
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inventiva (IVA), Tilray (TLRY) and Apellis Pharmaceuticals (APLS)
Tipranks
Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Apellis Pharmaceuticals (APLS)
Tipranks
Apellis Pharmaceuticals to be Acquired by Biogen in Merger
Tipranks
Wall Street Analysts Are Neutral on Top Healthcare Picks
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)
Tipranks
William Blair downgrades Apellis Pharmaceuticals (APLS) to a Hold
Tipranks
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD)
Motley Fool
Why Biogen Stock Sank While the Market Soared on Thursday
GlobeNewswire
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Tipranks
Mizuho Securities Remains a Hold on Apellis Pharmaceuticals (APLS)
Motley Fool
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
Tipranks
Cantor Fitzgerald Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
Tipranks
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
Tipranks
Analysts’ Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX)
Tipranks
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Apellis Pharmaceuticals (APLS)
GlobeNewswire
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS) and MannKind (MNKD)
Tipranks
Apellis price target lowered to $18 from $20 at Wedbush
Tipranks
Wedbush Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
Tipranks
Cantor Fitzgerald Remains a Buy on Apellis Pharmaceuticals (APLS)
Tipranks
RBC Capital Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Tipranks
Citi Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)
Tipranks
Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS)
Zacks Investment Research
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Motley Fool
Apellis (APLS) Q4 2025 Earnings Call Transcript
GlobeNewswire
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.